Zacks Investment Research upgraded shares of NOVABAY PHARMAC (NBY) from NEUTRAL to OUTPERFORM on November 06, 2012, with a target price of $1.50.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NOVABAY PHARMAC (NBY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment